CytomX

+$0.05 (+3.18%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CytomX and other ETFs, options, and stocks.

About CTMX

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.

CEO
Sean A. McCarthy
Employees
174
Headquarters
South San Francisco, California
Founded
2010

CTMX Key Statistics

Market cap
105.95M
Price-Earnings ratio
—
Dividend yield
—
Average volume
815.97K
High today
$1.63
Low today
$1.52
Open price
$1.61
Volume
587.26K
52 Week high
$7.85
52 Week low
$1.51

CTMX News

BenzingaMay 26

CytomX Therapeutics Initiates Dosing in Early-Stage Study Of Solid Tumor Settings

CytomX Therapeutics, Inc. CTMX initiated enrolment by dosing first patient in a Phase 1 dose-escalation study of CX-904 for patients with advanced solid tumors.

CTMX Earnings

-$0.50
-$0.33
-$0.17
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 4, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure